Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis
Read the article on our ERC grant “Clostridium-based Immunotherapy” which has been published on the CORDIS website in six languages at: